171 related articles for article (PubMed ID: 10194124)
21. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
22. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells.
Zheng R; Levis M; Piloto O; Brown P; Baldwin BR; Gorin NC; Beran M; Zhu Z; Ludwig D; Hicklin D; Witte L; Li Y; Small D
Blood; 2004 Jan; 103(1):267-74. PubMed ID: 12969963
[TBL] [Abstract][Full Text] [Related]
23. New cytokine-dependent acute myeloid leukemia cell line MUTZ-11 with disomic chromosome rearrangement t(16;17).
Hu ZB; Quentmeier H; Meyer C; Kaufmann M; MacLeod RA; Drexler HG
Leuk Res; 2004 May; 28(5):509-15. PubMed ID: 15068904
[TBL] [Abstract][Full Text] [Related]
24. Phosphoproteome analyses reveal specific implications of Hcls1, p21-activated kinase 1 and Ezrin in proliferation of a myeloid progenitor cell line downstream of wild-type and ITD mutant Fms-like tyrosine kinase 3 receptors.
Habif G; Grasset MF; Kieffer-Jaquinod S; Kuhn L; Mouchiroud G; Gobert-Gosse S
J Proteomics; 2013 Jan; 78():231-44. PubMed ID: 23017497
[TBL] [Abstract][Full Text] [Related]
25. Use of human leukemia-lymphoma cell lines in hematological research: effects of thrombopoietin on human leukemia cell lines.
Drexler HG; Quentmeier H
Hum Cell; 1996 Dec; 9(4):309-16. PubMed ID: 9183663
[TBL] [Abstract][Full Text] [Related]
26. Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells.
Nicholls SE; Winter S; Mottram R; Miyan JA; Whetton AD
Exp Hematol; 1999 Apr; 27(4):663-72. PubMed ID: 10210324
[TBL] [Abstract][Full Text] [Related]
27. Expression of the flt3 receptor and its ligand on hematopoietic cells.
Brasel K; Escobar S; Anderberg R; de Vries P; Gruss HJ; Lyman SD
Leukemia; 1995 Jul; 9(7):1212-8. PubMed ID: 7630197
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of two novel cytokine-responsive acute myeloid and monocytic leukemia cell lines, MUTZ-2 and MUTZ-3.
Hu ZB; Ma W; Zaborski M; MacLeod R; Quentmeier H; Drexler HG
Leukemia; 1996 Jun; 10(6):1025-40. PubMed ID: 8667638
[TBL] [Abstract][Full Text] [Related]
29. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
30. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias.
Carow CE; Levenstein M; Kaufmann SH; Chen J; Amin S; Rockwell P; Witte L; Borowitz MJ; Civin CI; Small D
Blood; 1996 Feb; 87(3):1089-96. PubMed ID: 8562934
[TBL] [Abstract][Full Text] [Related]
31. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells.
Turner AM; Lin NL; Issarachai S; Lyman SD; Broudy VC
Blood; 1996 Nov; 88(9):3383-90. PubMed ID: 8896403
[TBL] [Abstract][Full Text] [Related]
32. The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.
Tsapogas P; Mooney CJ; Brown G; Rolink A
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28538663
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Tse KF; Allebach J; Levis M; Smith BD; Bohmer FD; Small D
Leukemia; 2002 Oct; 16(10):2027-36. PubMed ID: 12357354
[TBL] [Abstract][Full Text] [Related]
34. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
Grandage VL; Everington T; Linch DC; Khwaja A
Br J Haematol; 2006 Nov; 135(3):303-16. PubMed ID: 16956345
[TBL] [Abstract][Full Text] [Related]
35. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.
Okuda K; Matulonis U; Salgia R; Kanakura Y; Druker B; Griffin JD
Exp Hematol; 1994 Oct; 22(11):1111-7. PubMed ID: 7925778
[TBL] [Abstract][Full Text] [Related]
36. The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis.
Piacibello W; Garetto L; Sanavio F; Severino A; Fubini L; Stacchini A; Dragonetti G; Aglietta M
Exp Hematol; 1996 Feb; 24(2):340-6. PubMed ID: 8641363
[TBL] [Abstract][Full Text] [Related]
37. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
38. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells.
Fenski R; Flesch K; Serve S; Mizuki M; Oelmann E; Kratz-Albers K; Kienast J; Leo R; Schwartz S; Berdel WE; Serve H
Br J Haematol; 2000 Feb; 108(2):322-30. PubMed ID: 10691863
[TBL] [Abstract][Full Text] [Related]
39. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Hartman AD; Wilson-Weekes A; Suvannasankha A; Burgess GS; Phillips CA; Hincher KJ; Cripe LD; Boswell HS
Exp Hematol; 2006 Oct; 34(10):1360-76. PubMed ID: 16982329
[TBL] [Abstract][Full Text] [Related]
40. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
